The Effect of Intravitreal Erythropoietin Injection for Refractive Diabetic Macular Edema
试验速览
- 阶段
- 2 期
- 入组人数
- 58
- 试验地点
- 1
- 主要终点
- best corrected visual acuity
研究概览
简要总结
after advent of RD photoreceptor degeneration Occurred. This process appears as a incredible and progressive event that will not stop till reattachment of RPE and neurosensory retina happened .
Process of degeneration begins from first hours of RD establishment Neuroprotection of photoreceptor following RD is a novel and debatable discussion encountered in recent years .
How to stop this phenomena and neuroprotective agent role in this issue are a new interest of researches.
In the study investigators are planning to perform a clinical trial to demonstrate the minocycline neuroprotective effect in a double blind design as this impact has been implicated previously in a animal study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patient with refractory diabetic macular edema at least one month after third injection
排除标准
- •previous vitreoretinal surgery previous glaucoma surgery glaucomatous patient open heart surgery active proliferative diabetic retinopathy one eye patients vitreous hemorrhage
研究组 & 干预措施
intravitreal injection of bevacizumab and erythropoietin
erythropoietin:
干预措施: injection of bevacizumab and erythropoietin (Drug)
intravitreal injection of bevacizumab
bevacizumab:1.25 mg
干预措施: injection of bevacizumab (Drug)
结局指标
主要结局
best corrected visual acuity
时间窗: 1 month
Snellen chart
次要结局
- Optical coherence tomography(1 month)
研究者
Zahra Rabbani Khah
Clinical Professor
Shahid Beheshti University of Medical Sciences